S'abonner

Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis - 11/01/21

Doi : 10.1016/j.jaad.2020.10.046 
Ofelia Baniandrés-Rodríguez, MD, PhD a, , Jaime Vilar-Alejo, MD b, Raquel Rivera, MD c, José Manuel Carrascosa, MD, PhD d, Esteban Daudén, MD, PhD e, Enrique Herrera-Acosta, MD, PhD f, Antonio Sahuquillo-Torralba, MD g, Fran J. Gómez-García, MD h, Lula María Nieto-Benito, MD a, Pablo de la Cueva, MD, PhD i, José Luis López-Estebaranz, MD, PhD j, Isabel Belinchón, MD, PhD k, Marta Ferrán Farrés, MD, PhD l, Mercè Alsina, MD, PhD m, Lourdes Rodríguez Fernández-Freire, MD n, Gregorio Carretero, MD, PhD b, Carmen García-Donoso, MD c, Ferrán Ballescá, MD d, Mar Llamas-Velasco, MD, PhD e, Enrique Herrera-Ceballos, MD, PhD f, Rafael Botella-Estrada, MD, PhD g, Diana Patricia Ruiz-Genao, MD j, Josep Riera-Monroig, MD m, Miguel Ángel Descalzo Gallego, MSc, PhD o, Ignacio García-Doval, MD, PhD o, p
and the

BIOBADADERM Study Group

Esteban Daudén, Mar Llamas-Velasco, Cristina Santamaría, Gregorio Carretero, Jaime Vilar-Alejo, Blanca Madrid Álvarez, Raquel Rivera, Carmen García-Donoso, Ma del Mar Onteniente Gomis, Diana Batista Cabrera, Carlos Ferrándiz, José Manuel Carrascosa, Ferrán Ballescá, Pablo de la Cueva, Patricia Molina Mejías, Isabel Belinchón, Carlos García Giner, Alfred Perez, Fran J. Gómez-García, Enrique Herrera-Ceballos, Enrique Herrera-Acosta, Eliseo Martínez-García, Cristina Sánchez, José Luis López-Estebaranz, Diana Patricia Ruiz-Genao, Elena García Zamora, Marta Ferrán Farrés, Mercè Alsina, Josep Riera, Sara Pedregosa Fauste, Ofelia Baniandrés, Lula María Nieto Benito, Desiree Molina, José Luis Sánchez-Carazo, Antonio Sahuquillo-Torralba, Rafael Botella-Estrada, Conrad Pujol Marco, Natalia Chaparro Aguilera, Verónica Massó López, Lourdes Rodríguez Fernández-Freire, Almudena Mateu Puchades, Sergio Santos, Marina Sáez Belló, Ángeles Flórez Menéndez, Laura Salgado, Beatriz González Sixto, Ma Teresa Abalde, Lucia Vilanova, Alexandra Perez Mariño, Noemí Eiris, Vicenta Prieto Marcos, Ignacio García-Doval, Miguel Ángel Descalzo Gallego, Marina de Vega Martínez

a Department of Dermatology, CEIMI, Hospital General Universitario Gregorio Marañón, Madrid, Spain 
b Department of Dermatology, Hospital Universitario de Gran Canaria Dr Negrín, Las Palmas de Gran Canaria, Spain 
c Department of Dermatology, Hospital Universitario 12 de Octubre, Madrid, Spain 
d Department of Dermatology, Hospital Universitari Germans Trias i Pujol, Badalona, Universidad Autónoma de Barcelona, Barcelona, Spain 
e Department of Dermatology. Hospital Universitario de La Princesa, Instituto de Investigación Sanitaria de La Princesa (IIS-IP), Madrid, Spain 
f Department of Dermatology, Hospital Universitario Virgen de la Victoria, Málaga, Spain 
g Department of Dermatology, Hospital Universitario y Politécnico La Fe; Instituto de Investigación Sanitaria La Fe (IIS La Fe), Valencia, Spain. Facultad de Medicina, Universidad de Valencia, Spain 
h Department of Dermatology, Hospital Universitario Reina Sofía, Cordoba, Spain 
i Department of Dermatology, Hospital Universitario Infanta Leonor, Madrid, Spain 
j Department of Dermatology, Hospital Universitario Fundación Alcorcón, Madrid, Spain 
k Department of Dermatology, Hospital General Universitario de Alicante-ISABIAL, Alicante, Spain 
l Department of Dermatology, Hospital del Mar, Parc de Salut Mar, Barcelona, Spain 
m Department of Dermatology, Hospital Clínic de Barcelona, UB, Barcelona Spain 
n Department of Dermatology. Hospital Virgen del Rocío, Sevilla, Spain 
o Research Unit. Fundación Piel Sana AEDV, Madrid, Spain 
p Department of Dermatology, Complexo Hospitalario Universitario de Vigo, Vigo, Spain 

Correspondence to: Ofelia Baniandrés-Rodríguez, MD, PhD, Fundación Piel Sana AEDV, Calle Ferraz 100, 28008 Madrid, Spain.Fundación Piel Sana AEDVCalle Ferraz 100Madrid28008Spain

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!


 Funding sources: The BIOBADADERM project is promoted by the Fundación Piel Sana Academia Española de Dermatología y Venereología, which receives financial support from the Spanish Medicines and Health Products Agency (Agencia Española de Medicamentos y Productos Sanitarios) and from pharmaceutical companies (Abbott/Abbvie, Almirall, Janssen, Leo Pharma, Lilly, Novartis and UCB). The following companies have also collaborated in the past: MSD and Pfizer.
 Collaborating pharmaceutical companies were not involved in the design and conduct of the study; collection, management, analysis and interpretation of data; preparation, review, or approval of the manuscript; decision to submit the manuscript for publication.
 Conflicts of interest: Dr Baniandrés-Rodríguez acted as a consultant and/or speaker for Janssen-Cilag, AbbVie, Pfizer, Novartis, Lilly, Celgene, Leo Pharma, and Almirall. Dr Vilar-Alejo participated as AB from Janssen, Novartis, AbbVie, Almirall and Celgene. Dr Rivera acted as consultant and/or speaker for and/or participated in clinical trials as IP for Abbvie, Almirall, Celgene, Janssen, Leo Pharma, Lilly, Novartis, MSD, and Pfizer-Wyeth. Dr Carrascosa has participated as speaker and/or advisor for Celgene, Janssen, Lilly, Novartis, Leo Pharma, Pfizer, MSD, Abbvie, and Biogen Amgen. Dr Dauden acted as consultant for Abbott, Amgen, Astellas, Centocor Ortho Biotech Inc, Galderma, Glaxo, Jansenn-Cilag, Leo Pharma, Novartis, Pfizer, MSD, and Celgene; received honoraria form Abbott, Amgen, Janssen-Cilag, Leo Pharma, Novartis, Pfizer, MSD, and Celgene; participated in a speakers bureau for Abbott, Pfizer, MSD, and Janssen; and received grants from Pfizer, Abbott, Janssen, and MSD. Dr Herrera-Acosta has served as consultant and/or speaker with Leo Pharma, Novartis, Janssen, Lilly, Celgene, and Abbvie. Dr Sahuquillo has served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Celgene, Janssen-Cilag, LEO Pharma, Lilly, Novartis, and Pfizer. Dr de la Cueva acted as a consultant and/or speaker for Janssen-Cilag, AbbVie, MSD, Pfizer, Novartis, Lilly, Almirall, UCB, Biogen, Celgene, Amgen, Sandoz, Sanofi, and Leo-Pharma. Dr López-Estebaranz participated as AB and received educational grants from Janssen, Abbvie, MSD, Lilly, Novartis, LeoPharma, and Pfizer. Dr Belinchón acted as a consultant and/or speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including Janssen Pharmaceuticals Inc, Almirall SA, Lilly, AbbVie, Novartis, Celgene, Biogen Amgen, Leo-Pharma, UCB, Pfizer-Wyeth, and MSD. Dr Ferran-Farrés has participated as speaker and/or advisor for Janssen, Lilly, Novartis, Pfizer, MSD, Abbvie Celgene, and Almirall. Dr Alsina gave expert testimony for Merck-Schering Plough, Pfizer, Janssen, Novartis, Lilly, and Abbott and has participated as speaker for Almirall, Janssen, and Gebro Pharma. Dr Rodriguez Fernandez-Freire acted as a consultant and speaker for Janssen-Cilag, AbbVie, MSD, Pfizer, Novartis, Lilly, Almirall, Celgene, and Leo-Pharma. Dr Carretero has been reimbursed by Janssen, Abbvie, Novartis, Pfizer, MSD, and Celgene for advisory service and conference. Dr García-Donoso participated as AB from AbbVie and Almirall and speaker for Janssen, Lilly, and Celgene. Dr Llamas-Velasco acted as a consultant and speaker and participated in clinical trials for Janssen-Cilag, AbbVie, Celgene, Pfizer, Novartis, Lilly, Almirall, and Leo-Pharma. Dr Herrera-Ceballos has served as a consultant and/or speaker for and/or participated in clinical trials as IP and sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Janssen-Cilag, LEO Pharma, Lilly, Novartis and Pfizer. Dr Botella-Estrada has served as a consultant and/or paid speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis, including AbbVie, Celgene, Janssen-Cilag, LEO Pharma, Lilly, Novartis, and Pfizer. Dr Ruiz-Genao has been reimbursed by Pfizer, Janssen, Celgene, Abbvie, Novartis, and LeoPharma for advisory services and conferences. Dr Riera-Monroig received travel grants for congresses from Abbvie, Almirall, Janssen, LEO-Pharma, and Novartis. Dr Garcia-Doval received travel grants for congresses from Abbvie, MSD, and Pfizer. None of the other authors has any conflicting interests to disclose.
 IRB status: Observational study. Approved (Biobadaderm: Hospital Universitario 12 de Octubre (216/07).
 Reprints not available from the authors.


© 2020  American Academy of Dermatology, Inc.. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 84 - N° 2

P. 513-517 - février 2021 Retour au numéro
Article précédent Article précédent
  • COVID-19 and health care disparities: Innovative ways to meet the dermatologic needs of patients experiencing homelessness
  • Samantha M. Guhan, Neera R. Nathan, Haya Raef, Margaret Cavanaugh-Hussey, Jennifer K. Tan
| Article suivant Article suivant
  • Analysis of availability of online dermatology appointments during the COVID-19 pandemic
  • Lilly Gu, Laura Xiang, Shari R. Lipner

Bienvenue sur EM-consulte, la référence des professionnels de santé.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.